Efficacy and Safety of Hizentra(®), a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency

Subcutaneous IgG treatment for primary immunodeficiencies (PI) is particularly well suited for children because it does not require venous access and is mostly free of systemic adverse events (AEs). In a prospective, open-label, multicenter, single-arm, Phase III study, 18 children and five adolesce...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Borte, Michael, Pac, Malgorzata, Serban, Margit, Gonzalez-Quevedo, Teresa, Grimbacher, Bodo, Jolles, Stephen, Zenker, Othmar, Neufang-Hueber, Jutta, Belohradsky, Bernd
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer US 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3221851/
https://ncbi.nlm.nih.gov/pubmed/21674136
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-011-9557-z
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares